Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Sarcoma 3Gynecologic 3Gastrointestinal 3Dermatologic 2Breast 2Genitourinary 1

Conditions

Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Ovarian Neoplasms 1Disorders of Sex Development 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × STA 9090 × Gynecologic × Clear all
NCT03783949 2025-06-11

EUDARIO

Universitaire Ziekenhuizen KU Leuven

Phase 2 Completed
122 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
12 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡